Potent and Safe
Active Immunotherapies
for a Cancer-Free Future

About Us

Scancell develops active immunotherapies for a cancer-free future by enhancing long-lasting tumour specific immunity. Our aim is to deliver safe, effective and patient-accessible therapies that are easy to administer in hard-to treat cancers.

Our Approach

Scancell is a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat cancers from its proprietary platforms Immunobody® and Moditope.

View pipeline

LATEST NEWS

View All News

Meet our leadership team

Our leadership team combines experienced and talented people who are committed to advancing our clinical programmes and translating innovative science for patient benefit.

Find out more

Phil L'Huillier

Chief Executive Officer

Professor Lindy Durrant

Chief Scientific Officer

David Schilansky

Interim Chief Financial Officer

Dr Nermeen Varawalla

Chief Medical Officer

Dr Mandeep Sehmi

Head of Business Development

Dr Callum Scott

Senior Vice President of Development

Dr Samantha Paston

Head of Translational Research

Dr Shamim Kazmi-Stokes

Head of Programme Management

Philip Angell-Manning

Head of CMC

Alex Hayward

Finance Director & Company Secretary

JOIN OUR MAILING LIST

Sign up for news updates to stay up to date with Scancell.